| abstract |
Novel compounds having the ability to inhibit 5-lipoxygenase enzyme and having formula (I) and the pharmaceutically acceptable salts thereof, wherein Ar1 is a heterocyclic moiety which is selected from imidazolyl, pyrrolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, indolyl, indazolyl and benzimidazolyl, which is bonded to X1 through a ring nitrogen atom, and which may be optionally substituted with one or two substituents selected from halo, hydroxy, cyano, amino, C¿1-4? alkyl and the like; X?1¿ is a direct bond or C¿1-4? alkylene; Ar?2¿ is phenylene optionally substituted with halo, hydroxy, cyano, amino and the like; X2 is -A-X- or -X-A- wherein A is a direct bond or C¿1-4? alkylene and X is oxy, thio, sulfinyl or sulfonyl; Ar?3¿ is phenylene, pyridylene, thienylene, furylene, oxazolylene or thiazolylene optionally substituted with one or two substituents selected from halo, hydroxy, cyano, amino, C¿1-4? alkyl and the like; R?1 and R2¿ are each C¿1-4? alkyl, or together they form a group of formula -D?1-Z-D2¿- which together with the carbon atom to which it is attached defines a ring having 3 to 8 atoms, wherein D?1 and D2¿ are C¿1-4? alkylene and Z is a direct bond or oxy, thio, sulfinyl, sulfonyl, or vinylene, and D?1 and D2¿ may be substituted by C¿1-3? alkyl; and Y is CONR?3R4¿, CN, C(R?3)=N-OR4, COOR3, COR3¿ or CSNR3R4, wherein R?3 and R4¿ are each H or C¿1-4? alkyl. These compounds are useful in the treatment or alleviation of inflammatory diseases, allergy and cardiovascular diseases in mammals and as the active ingredient in pharmaceutical compositions for treating such conditions. |